ArticleFrontiers in oncology2022

Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma.

Charles B Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.